Crinetics Pharmaceuticals (CRNX) Non Operating Investment Income (2023)
Crinetics Pharmaceuticals (CRNX) posted quarterly Non Operating Investment Income of -$470000.0 for Q1 2024, up 88.81% quarter-over-quarter from -$4.2 million in Q4 2023.
Powered by 
Analysis
Crinetics Pharmaceuticals (CRNX) Non Operating Investment Income (2023) Analysis & Trends
Crinetics Pharmaceuticals' Non Operating Investment Income history runs 3 years deep, the most recent figure standing at -$470000.0 for Q1 2024.
- In Q1 2024, Non Operating Investment Income changed N/A year-over-year to -$470000.0; the TTM figure through Dec 2024 stood at -$470000.0 (up 90.96% YoY), while the FY2024 annual figure was -$470000.0, up 90.96% from the prior year.
- Non Operating Investment Income for Q1 2024 stood at -$470000.0, up from -$4.2 million in the prior quarter.
- The five-year high for Non Operating Investment Income was -$470000.0 in Q1 2024, with the low at -$4.2 million in Q4 2023.
- The 3-year median for Non Operating Investment Income is -$1.0 million (2022), against an average of -$1.7 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Crinetics Pharmaceuticals | 8.99 Bn | 8.99 Bn | 24.96 Mn | - |